Monthly Rifampicin, Ofloxacin, and Minocycline for Leprosy Treatment
Author Information
Author(s): Sivakumaran Priyanka, de Barros Barbara, Antonio Dias Vivianne Lopes, Lockwood Diana N., Walker Stephen L.
Primary Institution: Hospital for Tropical Diseases, University College London Hospitals NHS Foundation Trust, London, United Kingdom
Hypothesis
What are the clinical outcomes and experiences of individuals treated with monthly rifampicin, ofloxacin, and minocycline for leprosy?
Conclusion
Monthly rifampicin, ofloxacin, and minocycline therapy is safe, effective, and leads to improvement in skin lesions and a decline in bacterial index.
Supporting Evidence
- 89.7% of individuals completed the monthly treatment.
- 58.6% of individuals experienced a leprosy reaction.
- Only one individual relapsed during the study period.
- 49 reports of adverse effects were mild or moderate.
- The most common adverse effect was orange discoloration of urine.
Takeaway
This study looked at how well a new leprosy treatment works, and it found that most people got better without serious side effects.
Methodology
A retrospective cohort study was conducted, collecting demographic and clinical data on individuals treated with mROM and their experiences through semi-structured interviews.
Potential Biases
Recall bias may affect the reliability of reported adverse effects from interviews conducted months or years after treatment.
Limitations
The small sample size and retrospective nature of the study may limit the generalizability of the findings.
Participant Demographics
{"gender_distribution":{"male":20,"female":9},"mean_age_at_diagnosis":39,"leprosy_classification":{"tuberculoid":4,"borderline_tuberculoid":6,"borderline_lepromatous":4,"lepromatous":14,"pure_neural":1}}
Statistical Information
P-Value
0.04
Confidence Interval
95% CI: 0.25 to 5.9
Statistical Significance
p = 0.04
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website